Are You Looking to Position Yourself as a Leader in the Antifibrotic Drug Development Field?
The 9th Antifibrotic Drug Development Summit returns to Boston this November 17–19, 2025, uniting 80+ drug developers from top pharma, innovative biotechs, and cutting-edge solution providers. As the industry’s premier forum for fibrosis R&D, this event is designed to tackle the most pressing challenges in antifibrotic drug development, from discovery through Phase 2.
Through deep engagement with the fibrosis community, we’ve identified their critical pain points, including:
- Bridging translational gaps with human-relevant models
- Validating biomarkers to quantify fibrosis regression and patient stratification
- Advancing novel modalities through antibody-drug conjugates, mRNA therapies, and pan-fibrotic approaches
- Designing competitive clinical programs in an era of GLP-1 competition and evolving regulatory expectations
Partner with us in 2025 to elevate your brand and secure direct access to our audience of senior decision-makers from companies like Pfizer, Eli Lilly, Novartis, and Madrigal Pharmaceuticals all actively investing in the development of antifibrotic therapies.
What the Summit Delivers for Partners:
Raise Your Brand Awareness
Showcase your solutions to decision-makers who rely on partners to bridge gaps in preclinical models, biomarkers, clinical studies.
Distinguish Your Solutions
Demonstrate your expertise in fibrosis-specific challenges, including:
- Preclinical models that replicate chronic fibrotic progression (e.g., precision-cut tissue slices).
- Non-invasive biomarkers to replace biopsies (e.g., collagen-targeted PET imaging).
- Cross-organ mechanistic insights to support pan-fibrotic claims.
- Clinical study design and optimisation.
Generate Commercial Opportunities
The 9th Antifibrotic Drug Development Summit’s intentionally curated forum fosters high-value connections between solution providers and the fibrosis leaders who need them most. With attendance capped to maintain an intimate environment, you’ll engage in meaningful dialogues with executives from clinical-stage biotechs like Arda Therapeutics, whose fibroblast-depleting ADC platform is attracting pharma partnership interest, and Alentis Therapeutics, advancing first-in-class anti-Claudin-1 monoclonal antibodies for multi-organ fibrosis reversal, along with BD teams from Novartis, Pfizer, and GSK attending to identify partners who can de-risk their path to Phase 2.
Powering Innovation in Antifibrotic Drug Development
Our attendees from 80+ leading biopharma companies, innovative biotechs, and top academic institutions are actively seeking partners with specialized expertise to overcome the field’s most pressing challenges, from target discovery to Phase 2 clinical validation. Whether you specialize in human-relevant disease models, non-invasive biomarkers, or translational CRO services, partnering with the 9th Antifibrotic Drug Development Summit connects you directly with senior decision-makers scouting solutions.
1
Preclinical & Translational Models
With fibrosis candidates failing in clinical trials due to translatability, our attendees urgently need human-relevant systems. Your 3D organoids, precision-cut tissue slices, or chronic fibrosis models can help them bridge this gap by better replicating disease progression and treatment responses seen in patients.
2
Biomarkers & Imaging Technologies
Proteomic panels, AI-powered histopathology tools, or novel tracers help developers quantify fibrosis reversal and stratify patients - critical for Phase 2 success and partnership deals.
3
Clinical Research Organisations
CROs help provide the operational expertise needed to navigate patient recruitment, endpoint validation, and organ-specific efficacy assessments. As developers like Mediar Therapeutics and Graviton Biosciences advance novel mechanisms, they seek CRO partners who understand both the biological nuances of fibrotic diseases and the evolving regulatory expectations - particularly for combination therapies and non-invasive endpoint.
Get In Touch:
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Thomas Walsh
Business Development Manager
Telephone: +1 617 455 4188
Email: sponsor@hansonwade.com